Certive Solutions Inc. (CBP.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -716.48 Thousand USD | 33.8% |
| 2021 | -1.65 Million USD | -94.1% |
| 2020 | -1.19 Million USD | 28.54% |
| 2019 | -1.48 Million USD | 32.9% |
| 2018 | -2.21 Million USD | 25.51% |
| 2017 | -2.97 Million USD | 19.13% |
| 2016 | -3.34 Million USD | 26.69% |
| 2015 | -5.01 Million USD | -176.55% |
| 2014 | -1.83 Million USD | -24.25% |
| 2013 | -1.45 Million USD | -67.91% |
| 2012 | -869.24 Thousand USD | -30.19% |
| 2011 | -667.69 Thousand USD | -380.18% |
| 2010 | -139.05 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -314.5 Thousand USD | -72.99% |
| 2023 Q1 | -181.8 Thousand USD | 41.14% |
| 2023 Q3 | -169.55 Thousand USD | 46.09% |
| 2022 Q4 | -308.88 Thousand USD | -18.83% |
| 2022 Q2 | -325.71 Thousand USD | 30.66% |
| 2022 Q3 | -259.94 Thousand USD | 20.19% |
| 2022 FY | - USD | 33.8% |
| 2022 Q1 | -469.77 Thousand USD | 40.36% |
| 2021 Q4 | -787.61 Thousand USD | -77.12% |
| 2021 Q1 | -455.07 Thousand USD | -64.66% |
| 2021 FY | - USD | -94.1% |
| 2021 Q2 | -373.67 Thousand USD | 17.89% |
| 2021 Q3 | -444.69 Thousand USD | -19.0% |
| 2020 Q4 | -276.37 Thousand USD | -14.18% |
| 2020 Q3 | -242.04 Thousand USD | 15.56% |
| 2020 Q2 | -286.64 Thousand USD | -22.81% |
| 2020 Q1 | -233.39 Thousand USD | -26.33% |
| 2020 FY | - USD | 28.54% |
| 2019 Q3 | -583.31 Thousand USD | -87.7% |
| 2019 Q2 | -310.76 Thousand USD | 23.67% |
| 2019 FY | - USD | 32.9% |
| 2019 Q1 | -407.14 Thousand USD | 49.69% |
| 2019 Q4 | -184.75 Thousand USD | 68.33% |
| 2018 Q3 | -575.1 Thousand USD | -58.54% |
| 2018 Q2 | -362.74 Thousand USD | 16.05% |
| 2018 Q4 | -809.32 Thousand USD | -40.73% |
| 2018 Q1 | -432.1 Thousand USD | 43.96% |
| 2018 FY | - USD | 25.51% |
| 2017 Q3 | -749.46 Thousand USD | -1.72% |
| 2017 FY | - USD | 19.13% |
| 2017 Q4 | -770.99 Thousand USD | -2.87% |
| 2017 Q2 | -736.78 Thousand USD | -2.94% |
| 2017 Q1 | -715.76 Thousand USD | 64.19% |
| 2016 FY | - USD | 26.69% |
| 2016 Q4 | -1.99 Million USD | -200.66% |
| 2016 Q2 | -640.89 Thousand USD | -100.67% |
| 2016 Q1 | -319.38 Thousand USD | 88.77% |
| 2016 Q3 | -664.73 Thousand USD | -3.72% |
| 2015 FY | - USD | -176.55% |
| 2015 Q2 | -1.33 Million USD | -316.98% |
| 2015 Q3 | -898.91 Thousand USD | 32.79% |
| 2015 Q4 | -2.84 Million USD | -216.25% |
| 2015 Q1 | -320.76 Thousand USD | 59.8% |
| 2014 Q2 | -403.83 Thousand USD | -784.62% |
| 2014 FY | - USD | -24.25% |
| 2014 Q4 | -797.99 Thousand USD | -40.84% |
| 2014 Q3 | -566.58 Thousand USD | -40.3% |
| 2014 Q1 | -45.65 Thousand USD | 90.19% |
| 2013 Q4 | -465.25 Thousand USD | -23.51% |
| 2013 FY | - USD | -67.91% |
| 2013 Q1 | -442.61 Thousand USD | -2837.59% |
| 2013 Q2 | -187.11 Thousand USD | 57.73% |
| 2013 Q3 | -376.68 Thousand USD | -101.31% |
| 2012 Q2 | -421.1 Thousand USD | 3.62% |
| 2012 Q1 | -436.92 Thousand USD | 31.62% |
| 2012 FY | - USD | -30.19% |
| 2012 Q3 | -178.49 Thousand USD | 57.61% |
| 2012 Q4 | -15.06 Thousand USD | 91.56% |
| 2011 Q2 | -8465.04 USD | -46.26% |
| 2011 Q3 | -10.4 Thousand USD | -22.97% |
| 2011 Q4 | -638.98 Thousand USD | -6038.74% |
| 2011 FY | - USD | -380.18% |
| 2011 Q1 | -5787.83 USD | 95.07% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | -2827.20 USD | 84.42% |
| 2010 Q2 | -18.14 Thousand USD | 0.0% |
| 2010 Q4 | -117.3 Thousand USD | -4049.22% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AI/ML Innovations Inc. | -1.66 Million CAD | 56.965% |
| Diagnamed Holdings Corp. | -100.27 Thousand CAD | -614.546% |
| Pangenomic Health Inc. | -2.71 Million CAD | 73.579% |
| nDatalyze Corp. | -290.5 Thousand CAD | -146.637% |
| Treatment.Com International Inc. | -3.64 Million CAD | 80.351% |
| Unidoc Health Corp. | -2.18 Million CAD | 67.178% |